David K. Gaffney

ORCID: 0000-0002-5752-1611
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Endometrial and Cervical Cancer Treatments
  • Ovarian cancer diagnosis and treatment
  • Cervical Cancer and HPV Research
  • Advanced Radiotherapy Techniques
  • Uterine Myomas and Treatments
  • Breast Cancer Treatment Studies
  • Management of metastatic bone disease
  • Colorectal and Anal Carcinomas
  • Advances in Oncology and Radiotherapy
  • Endometriosis Research and Treatment
  • Lymphoma Diagnosis and Treatment
  • Multiple and Secondary Primary Cancers
  • Cancer Risks and Factors
  • Global Cancer Incidence and Screening
  • Cancer survivorship and care
  • Radiomics and Machine Learning in Medical Imaging
  • Radiation Therapy and Dosimetry
  • Breast Lesions and Carcinomas
  • Sarcoma Diagnosis and Treatment
  • BRCA gene mutations in cancer
  • Cutaneous lymphoproliferative disorders research
  • Lung Cancer Treatments and Mutations
  • Estrogen and related hormone effects
  • Breast Implant and Reconstruction
  • Effects of Radiation Exposure

Huntsman Cancer Institute
2016-2025

University of Utah
2016-2025

Cleveland Clinic
2023-2024

Cancer Institute (WIA)
2023-2024

University Hospitals Seidman Cancer Center
2023-2024

Stanford University
2023

International Federation of Gynaecology and Obstetrics
2023

Huntsman (United States)
2007-2022

Suwon Research Institute
2016-2020

Istituto Nazionale di Fisica Nucleare, Sezione di Milano
2013-2020

Cervical cancer is a malignant epithelial tumor that forms in the uterine cervix. Most cases of cervical are preventable through human papilloma virus (HPV) vaccination, routine screening, and treatment precancerous lesions. However, due to inadequate screening protocols many regions world, remains fourth-most common women globally. The complete NCCN Guidelines for Cancer provide recommendations diagnosis, evaluation, cancer. This manuscript discusses guiding principles workup, staging,...

10.6004/jnccn.2019.0001 article EN Journal of the National Comprehensive Cancer Network 2019-01-01

Endometrial carcinoma is a malignant epithelial tumor that forms in the inner lining, or endometrium, of uterus. most common gynecologic malignancy. Approximately two-thirds endometrial cases are diagnosed with disease confined to The complete NCCN Guidelines for Uterine Neoplasms provide recommendations diagnosis, evaluation, and treatment cancer uterine sarcoma. This manuscript discusses guiding principles staging, early-stage as well evidence these recommendations.

10.6004/jnccn.2018.0006 article EN Journal of the National Comprehensive Cancer Network 2018-02-01

Abstract Introduction Many advances in the understanding of pathologic and molecular features endometrial cancer have occurred since FIGO staging was last updated 2009. Substantially more outcome biological behavior data are now available regarding several histological types. Molecular genetic findings accelerated publication The Cancer Genome Atlas (TCGA) provide improved clarity on diverse nature this collection cancers their differing prognostic outcomes. goals new system to better define...

10.1002/ijgo.14923 article EN cc-by International Journal of Gynecology & Obstetrics 2023-06-20

Adenocarcinoma of the endometrium (also known as endometrial cancer, or more broadly uterine cancer carcinoma corpus) is most common malignancy female genital tract in United States. It estimated that 65,950 new cases will have occurred 2022, with 12,550 deaths resulting from disease. Endometrial includes pure endometrioid and carcinomas high-risk histology (including serous carcinoma, clear cell carcinosarcoma [also malignant mixed Müllerian tumor], undifferentiated/dedifferentiated...

10.6004/jnccn.2023.0006 article EN Journal of the National Comprehensive Cancer Network 2023-02-01

We compared the outcome of breast-conserving surgery and radiotherapy in BRCA1/2 mutation carriers with breast cancer versus that matched sporadic controls.A total 160 were 445 controls cancer. Primary end points rates in-breast tumor recurrence (IBTR) contralateral cancers (CBCs). Median follow-up was 7.9 years for 6.7 controls.There no significant difference IBTR overall between controls; 10- 15-year estimates 12% 24% 9% 17% controls, respectively (hazard ratio [HR], 1.37; P = .19)....

10.1200/jco.2005.02.7888 article EN Journal of Clinical Oncology 2006-04-25

The NCCN Guidelines for Cervical Cancer provide interdisciplinary recommendations treating cervical cancer. These Insights summarize the Panel’s discussion and major guideline updates from 2014 2015. recommended systemic therapy options recurrent metastatic cancer were amended upon panel review of new survival data FDA’s approval bevacizumab late-stage This article outlines relevant provides insight into decisions regarding various combination regimens. Additionally, a section was added to...

10.6004/jnccn.2015.0055 article EN Journal of the National Comprehensive Cancer Network 2015-04-01

The NCCN Guidelines for Cervical Cancer provide recommendations diagnostic workup, staging, and treatment of patients with the disease. These Insights focus on recent updates to guidelines, including changes first- second-line systemic therapy recurrent or metastatic disease, emerging evidence a new histopathologic classification system HPV-related endocervical adenocarcinoma.

10.6004/jnccn.2020.0027 article EN Journal of the National Comprehensive Cancer Network 2020-06-01

Purpose NRG Oncology/RTOG 1203 was designed to compare patient-reported acute toxicity and health-related quality of life during treatment with standard pelvic radiation or intensity-modulated therapy (IMRT) in women cervical endometrial cancer. Methods Patients were randomly assigned four-field (RT) IMRT treatment. The primary end point change GI from baseline the RT, measured bowel domain Expanded Prostate Cancer Index Composite (EPIC). Secondary points included urinary toxicity,...

10.1200/jco.2017.77.4273 article EN Journal of Clinical Oncology 2018-07-10

The NCCN Guidelines for Uterine Neoplasms provide recommendations diagnostic workup, clinical staging, and treatment options patients with endometrial cancer or uterine sarcoma. These Insights focus on the recent addition of molecular profiling information to aid in accurate diagnosis, classification, sarcomas.

10.6004/jnccn.2021.0038 article EN Journal of the National Comprehensive Cancer Network 2021-08-01

The NCCN Guidelines for Cervical Cancer provide recommendations all aspects of management cervical cancer, including the diagnostic workup, staging, pathology, and treatment. guidelines also include details on histopathologic classification cancer regarding features, molecular profiles, clinical outcomes. treatment landscape advanced is evolving constantly. These Insights a summary recent updates systemic therapy recurrent or metastatic disease.

10.6004/jnccn.2023.0062 article EN Journal of the National Comprehensive Cancer Network 2023-12-01

Introduction: Many advances in the understanding of pathologic and molecular features endometrial cancer have occurred since FIGO staging was last updated 2009.Substantially more outcome biological behavior data are now available regarding several histological types.Molecular genetic findings accelerated publication The Cancer Genome Atlas (TCGA) provide improved clarity on diverse nature this collection cancers their differing prognostic outcomes.The goals new system to better define these...

10.3802/jgo.2023.34.e85 article EN cc-by-nc Journal of Gynecologic Oncology 2023-01-01

Vulvar cancer is annually diagnosed in an estimated 6,470 individuals and the vast majority are histologically squamous cell carcinomas. accounts for 5% to 8% of gynecologic malignancies. Known risk factors vulvar include increasing age, infection with human papillomavirus, cigarette smoking, inflammatory conditions affecting vulva, immunodeficiency. Most neoplasias at early stages. Rarer histologies exist melanoma, extramammary Paget’s disease, Bartholin gland adenocarcinoma, verrucous...

10.6004/jnccn.2024.0013 article EN Journal of the National Comprehensive Cancer Network 2024-03-01

PURPOSE: Recent laboratory data suggest a role for BRCA1/2 in the cellular response to DNA damage. There is paucity of clinical data, however, examining effect radiotherapy (RT), which causes double-strand breaks, on breast tissue from mutation carriers. Thus goals this study were compare rates radiation-associated complications, in-breast tumor recurrence, and distant relapse women with mutations treated breast-conserving therapy (BCT) using RT observed sporadic disease. PATIENTS AND...

10.1200/jco.2000.18.19.3360 article EN Journal of Clinical Oncology 2000-10-19

Malignant phyllodes tumor is a rare and potentially aggressive breast neoplasm. Little information available regarding the optimal management of these lesions rarer still are data survival. The current study used large population database to determine prognostic factors that predict cause-specific survival (CSS).Data were obtained from Surveillance, Epidemiology, End Results Program (SEER) for years 1983-2002. Women receiving resection primary nonmetastatic malignant included (n = 821)....

10.1002/cncr.22228 article EN Cancer 2006-09-22

Abstract BACKGROUND Survivors of non‐Hodgkin lymphoma (NHL) are at increased risk for developing secondary malignancies. For the current study, authors quantitated this in a group NHL survivors over 30 years follow‐up. METHODS Standardized incidence ratios (observed‐to‐expected [O/E] ratio) and absolute excess malignancies were assessed 77,876 patients who diagnosed with between 1973 2001 from centers that participated National Cancer Institute's Surveillance, Epidemiology, End Results...

10.1002/cncr.21971 article EN Cancer 2006-05-17

Adenocarcinoma of the endometrium (also known as endometrial cancer or more broadly uterine carcinoma corpus) is most common malignancy female genital tract in United States. An estimated 49,560 new cases will occur 2013, with 8190 deaths resulting from disease. Uterine sarcomas (stromal/mesenchymal tumors) are uncommon malignancies, accounting for approximately 3% all cancers. The NCCN Guidelines Neoplasms describe malignant epithelial carcinomas and sarcomas; each these major categories...

10.6004/jnccn.2014.0025 article EN Journal of the National Comprehensive Cancer Network 2014-02-01
Coming Soon ...